6,860 Merck & Co., Inc. $MRK Shares Sold by QV Investors Inc.

Key Points

• QV Investors cut its Merck stake by 37.3%, selling 6,860 shares and retaining 11,507 shares valued at approximately $1.67 million. Institutional investors collectively own 76.07% of MRK.
• Analyst sentiment remains positive, with 17 Buy ratings and 10 Holds, producing a consensus “Moderate Buy” rating and an average price target of $151.92.
• Merck exceeded quarterly revenue and EPS expectations and pays a $0.85 quarterly dividend, but investors remain focused on Keytruda patent-cliff risk and whether newer cancer treatments can replace future sales.

QV Investors Inc. decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 37.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 11,507 shares of the company's stock after selling 6,860 shares during the period. QV Investors Inc.'s holdings in Merck & Co., Inc. were worth $1,672,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of MRK. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $30,000. Bullseye Investment Management LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Graney & King LLC boosted its stake in Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after purchasing an additional 200 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $41,000. Finally, Evergreen Advisors LLC purchased a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $43,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Ratings Changes

MRK has been the topic of a number of recent analyst reports. UBS Group upped their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Rothschild & Co Redburn raised their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, July 6th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 25th. Wolfe Research boosted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a report on Tuesday, August 25th. Finally, Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a report on Friday, September 4th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $151.92.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last three months. Company insiders own 0.17% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Merck & Co., Inc. Stock Up 3.2%

NYSE:MRK opened at $148.19 on Wednesday. The firm has a market capitalization of $365.62 billion, a P/E ratio of 118.55, a PEG ratio of 6.64 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The company's fifty day moving average price is $146.22 and its 200-day moving average price is $129.67. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.